Bayer sues Russian company trying to market generic Xarelto
German pharma major Bayer (BAYN: DE) has filed a lawsuit against the Russian manufacturer of generic drugs Medisorb, The Pharma Letter’s local correspondent reports.
The latter received permission to produce the drug with the international non-proprietary name (INN) rivaroxaban, marketed under the trade name Xarelto, which is protected by a Bayer patent until December 4, 2024. In this regard, the plaintiff asks the court to cancel state registration of the drug rivaroxaban Medisorb with the same active ingredient, and to stop its production, use and storage.
The drug is used to treat deep vein thrombosis and pulmonary embolism. In 2019-2020, the Russian Ministry of Health recommended it for the prevention, diagnosis and treatment of COVID-19. According to the Russian State Register of Medicines (GRLS), Medisorb registered rivaroxaban Medisorb in July 2022. The drug certificate is valid until July 2027.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze